Skip to main content Accessibility help

The Pharmacological Treatment of Autistic Spectrum Disorders

  • Thomas Owley


What role do medications play in the overall treatment of autistic spectrum disorders? In this review, the decision-making process involving identifying symptoms, initiating a pharmacological intervention, and monitoring that process is discussed. A review of the literature with an emphasis on controlled trials in autistic spectrum disorders is also undertaken.


Corresponding author

Please direct all correspondence to: Thomas B. Owley, MD, University of Chicago Department of Psychiatry, Division of Child and Adolescent Psychiatry, Office W451, 5841 South Maryland Avenue M/C 3077, Chicago, IL 60637. Tel: 773-702-4536; Fax: 773-702-9929; E-mail:


Hide All
1.Cook, EH Jr., Rowlett, R, Jaselskis, C, Leventhal, BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31;739745.
2.Gordon, C, State, R, Nelson, J, Hamburger, S, Rapoport, J. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50:441447.
3.Awad, GA. The use of selective serotonin reuptake inhibitors in young children with pervasive developmental disorders: some clinical observations. Can J Psychiatry. 1996;41:361366.
4.Brodkin, ES, McDougle, CJ, Naylor, ST, Cohen, DJ, Price, LH. Clomipramine in adults with pervasive developmental disorders: a prospective openlabel investigation. J Child Adolesc Psychopharmacol. 1997;7:109121.
5.McDougle, CJ, Epperson, CN, Price, LH, Gelernter, J. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry. 1998;3:270273.
6.Posey, DJ, Walsh, KH, Wilson, GA, McDougle, CJ. Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol. 1999;9:273276.
7.Chaziuddin, M, Tsai, L, Ghaziuddin, N. Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry. 1991;30:508509.
8.Kroenke, K, West, SL, Swindle, R, Gilsenan, A, Eckert, CJ, Dolor, R, et al.Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286:29472955.
9.Goodman, WK, McDougle, CJ, Price, LH. Pharmacotherapy of obsessive-compulsive disorder. J Clin Psychiatry. 1992;53(suppl):2937.
10.Remington, G, Sloman, L, Konstantareas, M, Parker, K, Gow, R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21:440444.
11.Cook, E, Rowlett, R, Jaselskis, C, Leventhal, B. Fluoxetine treatment of patients with autism and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31:739745.
12.Ilellings, JA, Kelley, LA, Gabrielli, WF, Kilgore, E, Shah, P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry. 1996;57:333336.
13.Posey, DJ, McDougle, CJ. Pharmacotherapeutic management of autism. Expert Opin Pharmacother. 2001;2:587600.
14.Cook, E, Leventhal, B. The serotonin system in autism. Curr Opin Pediatr. 1996:8:348354.
15.Aman, MG, Van Bourgondien, ME, Wolford, PL, Sarphare, G. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry. 1995;34:16721681.
16.Martin, A, Scahill, L, Klin, A, Volkmar, FR. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry. 1999;38:923931.
17.Klin, A, Volkmar, F, Schultz, R, Pauls, D, Cohen, DJ. Asperger's syndrome: phenomenology, neuropsychology, and neurobiology. Paper presented at: the 44th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada: October 16, 1997.
18.Aman, M, Langworthy, K. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord. 2000;30:451459.
19.Campbell, M, Fish, B, David, R, Shapiro, T, Collins, P, Koh, C. Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Child Schizophr. 1972;2:343358.
20.Campbell, M, Small, AM, Collins, PJ, Friedman, E, David, R, Genieser, N. Levodopa and levoamphetamine: a crossover study in young schizophrenicchildren. Curr Ther Res Clin Exp. 1976;19:7086.21.
21.Birmaher, B, Quintana, H, Greenhill, LL. Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry. 1988;27:248251.
22.Yuwiler, A, Brammer, GL, Morley, JE, Raleigh, MJ, Flannery, JW, Geller, E. Short-term and repetitive administration of oral tryptophan in normal men –effects on blood tryptophan, serotonin, and kynurenine concentrations. Arch Gen Psychiatry. 1981;38:619626.
23.Realmuto, GM, August, GJ, Garfinkel, B. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989;9:122125.
24.Schmidt, K. The effect of stimulant medication in childhood-onset pervasive developmental disorder–a case report. J Dev Behav Pediatr. 1982;3:244246.
25.Sporn, A, Pinsker, H. Use of stimulant medication in treating pervasive developmental disorder. Am J Psychiatry. 1981;138:997.
26.Strayhorn, JM Jr. Rapp, N, Donina, W, Strain, PS. Randomized trial of methylphenidate for an autistic child. J Am Acad Child Adolesc Psychiatry. 1988;27:244247.
27.Vitriol, C, Farber, B. Stimulant medication in certain childhood disorders. Am J Psychiatry. 1981;138:15171518.
28.Volkmar, FR, Stier, DM, Cohen, DJ. Age of recognition of pervasive developmental disorder. Am J Psychiatry. 1985;142:14501452.
29.Quintana, H, Birmaher, B, Stedge, D, et al.Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25:283294.
30.Handen, BL, Johnson, CR, Lubetsky, M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30:245255.
31.Jaselskis, CA, Cook, EH, Fletcher, KE, Leventhal, BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12:322327.
32.Fankhauser, MP, Karumanchi, VC, German, ML, Yates, A, Karumanchi, SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry. 1992;53:7782.
33.Williams, DT, Mehl, R, Yudofsky, S, Adams, D, Roseman, B. The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. J Am Acad Child Adolesc Psychiatry. 1982;21:129135.
34.Ratey, J, Bemporad, J, Sorgi, P, et al.Brief report: open trial effects of betablockers on speech and social behaviors in 8 autistic adults. J Autism Dev Disord. 1987;17:439446.
35.Fish, B, Shapiro, T, Campbell, M. Long-term prognosis and the response of schizophrenic children to drug therapy: A controlled study of trifluoperazine. Am J Psychiatry. 1966;123:3239.
36.Campbell, M, Anderson, LT, Meier, M, et al.A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry. 1976;17:640655.
37.Cohen, IL, Campbell, M, Posner, D, Small, AM, Triebel, D, Anderson, LT. Behavioral effects of haloperidol in young autistic children. An objective analysis using a within subject reversal design. J Am Acad Child Psychiatry. 1980;19:665677.
38.Naruse, H, Nagahata, M, Nakane, Y, Shirahashi, K, Takesada, M, Yamazaki, K. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiat. 1982;48:173184.
39.Anderson, LT, Campbell, M, Grega, DM, Perry, R, Small, AM, Green, WH. Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry. 1984;141:11951202.
40.Anderson, LT, Campbell, M, Adams, P, Small, AM, Perry, R, Shell, J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;9:227239.
41.Perry, R, Campbell, M, Adams, P, Lynch, N, Spencer, EK. Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry. 1989;28:8792.
42.Ernst, M, Magee, HJ, Gonzalez, NM, Locascio, JJ, Rosenberg, CR, Campbell, M. Pimozide in autistic children. Psychopharmacol Bull. 1992;28:187191.
43.Campbell, M, Adams, P, Perry, R, Spencer, EK, Overall, JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull. 1988;24:251255.
44.Wilmut, I, Schnieke, AE, McWhir, J, Kind, AJ, Campbell, KHS. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997;385:810813.
45.McDougle, CJ, Holmes, JP, Bronson, MR, et al.Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry. 1997;36:685693.
46.Unis, A, Cook, E, Vincent, J, Gjerde, D, Perry, B, Mason, C, et al.Platelet serotonin measures in adolescents with conduct disorder. Biol Psychiatry. 1997;42:553559.
47.Barber, J, Cross, I, Douglas, F, Nicholson, J, Moore, K, Browne, C. Neurofibromatosis pseudogene amplification underlies euchromatic cytogenetic duplications and triplications of proximal 15q. Hum Genet. 1998;103:600607.
48.Potenza, MN, Holmes, JP, Kanes, SJ, McDougle, CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999;19:3744.
49.Masi, G, Cosenza, A, Mucci, M, Brovedani, P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2001;40:12061214.
50.McDougle, CJ, Holmes, JP, Carlson, DC, Pelton, GH, Cohen, DJ, Price, LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55:633641.
51.Hellings, JA, Zarcone, JR, Crandall, K, Wallace, D, Schroeder, SR. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol. 2001;11:229238.
52.Volkmar, FR, Nelson, DS. Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry. 1990;29:127129.
53.Di Martino, A, Tuchman, RF. Antiepileptic drugs: affective use in autism spectrum disorders. Pediatr Neurol. 2001;25:199207.
54.Plioplys, A. Autism: Electroencephalographic abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med. 1994;148:220222.
55.Childs, JA, Blair, JL. Valproic acid treatment of epilepsy in autistic twins. J Neurosci Nurs. 1997;29:244248.
56.Damore, J, Stine, J, Brody, L. Medication-induced hypomania in Asperger's disorder. J Am Acad Child Adolesc Psychiatry. 1998;37:248249.
57.Hollander, E, Dolgoff-Kaspar, R, Cartwright, C, Rawitt, R, Novotny, S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry. 2001;62:530534.
58.Deonna, T, Ziegler, AL, Moura-Serra, J, Innocenti, G. Autistic regression in relation to limbic pathology and epilepsy: report of two cases. Dev Med Child Neurol. 1993;35:166176.
59.Komoto, J, Usui, S, Hirata, J. Infantile autism and affective disorder. J Autism Dev Disord. 1984;14:8184.
60.Belsito, K, Law, P, Kirk, K, Landa, R, Zimmerman, A. Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31:175181.
61.King, B. Wright, D, Handen, B, et al.A double-blind, placebo-controlled study of amantidine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:658665.
62.Brent, DA, Crumrine, PK, Varma, RR, Allan, M, Allman, C. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics. 1987;80:909917.
63.Vining, EPG, Mellits, D, et al.Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics. 1987;80:165174.
64.Campbell, M, Anderson, L, Small, A, Adams, P, Gonzalez, N, Ernst, M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry. 1993;32:12831291.
65.Zingarelli, G, Ellman, G, Hom, A, Wymore, M, Heidorn, S, Chicz-DeMet, A. Clinical effects of naltrexone on autistic behavior. Am J Ment Retard. 1992;97:5763.
66.Willemsen-Swinkels, SHN, Buitelaar, JK, Weijnen, FG, Van Engeland, H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry. Research 1995;58:203215.
67.Herman, B, Asleson, G, Papero, P. Acute and chronic naltrexone decreases the hyperactivity of autism. Abstr Soc Neurosci. 1993:Abstract 732.3.
68.Willemsen-Swinkels, SHN, Buitelaar, JK, Van Engeland, H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry. 1996;39:10231031.
69.Willemsen-Swinkels, SH, Buitelaar, JK, van Berckelaer-Onnes, IA, van Engeland, H. Brief report: six months continuation treatment in naltrex-one- responsive children with autism: an open-label case-control design. J Autism Dev Disord. 1999;29:167169.
70.Percy, AK, Glaze, DG, Schultz, RJ, Zoghbi, HY, Williamson, D, Frost, J al.Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann Neurol. 1994;35:464470.
71.Campbell, M, Fish, B, Korein, J, Shapiro, T, Collins, P, Koh, C. Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children. J Autism Child Schizophr. 1972:2:234263.
72.Buitelaar, JK, van der Gaag, RJ, van der Hoeven, J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry. 1998;59:5659.
73.Carlsson, ML. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy. J Neural Transm. 1998;105(4–5):525535.
74.Martineau, J, Barthelemy, C, Cheliakine, C, Lelord, G. Brief report: an open middle-term study of combined vitamin B6- magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. J Autism Dev Disord. 1988;18:435447.
75.Kleijnen, J, Knipschild, P. Niacin and vitamin B6 in mental functioning: a review of controlled trials in humans. Biol Psychiatry. 1991;29:931–41.
76.Geller, E, Ritvo, ER, Freeman, BJ, Yuwiler, A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Eng J Med. 1982;307:165169.
77.Aman, MG, Kern, RA. Review of fenfluramine in the treatment of the developmental disabilities. J Amer Acad Child Adolesc Psychiatry. 1989;28:549565.
78.Leventhal, BL, Cook, EH Jr, Morford, M, Ravitz, AJ, Heller, W, Freedman, DX. Clinical and neurochemical effects of fenfluramine in children with autism. J Neuropsychiatry Clin Neurosci. 1993:5:307315.
79.Aman, MG, Kern, RA, Arnold, LE, McGhee, DE. Fenfluramine and mental retardation. J Am Acad Child Adolesc Psychiatry. 1991;30:507508.
80.Schuster, CR, Lewis, M, Seiden, LS. Fenfluramine: neurotoxicity. Psychopharm Bull. 1986;22:148151.
81.Horvath, K, Stefanatos, G, Sokolski, KN, Wachtel, R, Nabors, L, Tildon, JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998;9:915.
82.Sandler, AD, Sutton, KA, DeWeese, J, Girardi, MA, Sheppard, V, Bodfish, JW. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999;341:18011806.
83.Chez, MG, Buchanan, CP, Bagan, BT, et al.Secretin and autism: a two-part clinical investigation. J Autism Dev Disord 2000;30:8794.
84.Dunn-Geier, J, Ho, HH, Auersperg, E, et al.Effect of secretin on children with autism: a randomized controlled trial. DevMed Child Neurol. 2000:42:796802.
85.Roberts, W, Weaver, L, Brian, J, et al.Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics. 2001;107:E71.
86.Coniglio, SJ, Lewis, JD, Lang, C, Burns, TG, Subhani-Siddique, R, Weintraub, A, et al.A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr. 2001;138:649655.
87.Owley, T, McMahon, W, Cook, EH, et al.Multi-site, double-blind, placebo-controlled trial of porcine secretin in autism. J Am Acad Child Adolesc Psychiatry. 2001;40:12931299.
88.Aman, M. Aberrant Behavior Checklis-Community. East Aurora, NY: Slosson Educational Publications; 1994.

The Pharmacological Treatment of Autistic Spectrum Disorders

  • Thomas Owley


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed